Hydrophilic Matrix Tablets for Oral Controlled Release

This detailed volume addresses key issues and subtle nuances involved in developing hydrophilic matrix tablets as an approach to oral controlled release. It brings together information from more than five decades of research and development on hydrophilic matrix tablets and provides perspective on contemporary issues. Twelve comprehensive chapters explore a variety of topics including polymers (hypromellose, natural polysaccharides and polyethylene oxide) and their utilization in hydrophilic matrices, critical interactions impacting tablet performance, in vitro physical and imaging techniques, and microenvironmental pH control and mixed polymer approaches, among others. In one collective volume, Hydrophilic Matrix Tablets for Oral Controlled Release provides a single source of current knowledge, including sections of previously unpublished data. It is an important resource for industrial and academic scientists investigating and developing these oral controlled release formulations.

Peter Timmins is Executive Director in Drug Product Science and Technology at Bristol-Myers Squibb Research and Development. His group, based in Moreton, U.K. and New Brunswick, USA, is responsible for creating, adapting, and applying drug delivery technology for oral drug candidates, including those requiring modified release technology. He has a degree in pharmacy and a PhD in pharmaceutical chemistry, both from the University of Bradford in the U.K. Dr. Timmins is a member of the Royal Pharmaceuticals Society of Great Britain. He has many ongoing academic collaborations in the area of oral drug delivery and is a visiting or honorary full professor at the schools of pharmacy at Aston, Bradford and Nottingham in the U.K. He is author or co-author of more than seventy publications, including several books and book chapters, and inventor or co-inventor on thirty patents.

Samuel Pygall is currently an Associate Director and Patient Services Manager at MSD U.K. He was awarded a Master of Pharmacy and a PhD in Pharmaceutical Science from the University of Nottingham in the U.K. Dr. Pygall has a core interest in fostering collaboration between academia and industry to form innovative patient-centric healthcare solutions. He holds a visiting lecturer position at Aston School of Pharmacy in the U.K. and is a U.K.-registered pharmacist, member of the Royal Pharmaceutical Society of Great Britain and past committee member of the United Kingdom and Ireland Controlled Release Society (UKICRS).

Colin Melia is Associate Professor at the School of Pharmacy, University of Nottingham, U.K. He has widely published, provided expert opinions on modified release dosage forms and has been engaged in collaborative research and consultancy with some sixty pharmaceutical and allied companies worldwide. His research group, Formulation Insights, focuses on the elucidation of drug release mechanisms that underlie modified release behaviour. At Nottingham University, he teaches medicines design and has twice won Lord Dearing Awards for outstanding contributions to teaching and student learning.